Quell Pharma

Quell Therapeutics is a private UK cell therapy biotech developing engineered regulatory T cell therapies for severe immune-mediated diseases. The company focuses on autologous CAR-Treg products designed to restore immune tolerance in transplantation, autoimmune, and inflammatory disorders, and it is also building allogeneic iPSC-derived Treg capabilities. Its lead clinical programs include QEL-001 in liver transplantation and QEL-005 in complex autoimmune disease, while partnered programs with AstraZeneca target type 1 diabetes and inflammatory bowel disease. Quell differentiates itself through a multi-modular Treg engineering platform, proprietary Foxp3 Phenotype Lock technology, and integrated manufacturing expertise intended to improve Treg stability, potency, persistence, and scalability.